Cargando…
Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives
SIMPLE SUMMARY: Around 5–10% of advanced melanoma patients progress early on anti-BRAF targeted therapy and 20–30% respond only with the stabilization of the disease. Presumably, these patients could benefit more from first-line immunotherapy. Resistance to BRAF/MEK inhibitors is generated by geneti...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102921/ https://www.ncbi.nlm.nih.gov/pubmed/35565444 http://dx.doi.org/10.3390/cancers14092315 |